Summary
This article discusses promising strategies in the management of treatment-resistant major depressive disorder. These include the use of pharmacologic approaches to modulate the hypothalamic-pituitary-adrenal axis, glutamatergic system, and endogenous opioid system, as well as nonpharmacologic approaches such as deep brain stimulation.
- major depressive disorder
- hypothalamic-pituitary-adrenal axis
- glutamatergic system
- endogenous opioid system
- deep brain stimulation
- mifepristone
- ketamine
- botulinum toxin
- pharmacogenetics
- psychiatry & psychology clinical trials
- © 2015 SAGE Publications